Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

24,446 total articles

Core Molding Technologies Extends Credit Facility Through 2031, Increasing Financial Flexibility for Strategic Growth

Core Molding Technologies Extends Credit Facility Through 2031, Increasing Financial Flexibility for Strategic Growth

Core Molding Technologies, a leading engineered materials company listed on NYSE American under ticker CMT, announced the successful amendment and extension of its credit agreement through 2031. The new facility includes a $50 million delayed draw term loan and a $50 million revolving credit facility with covenant-light terms and interest based on …

Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas

Daxor Corporation Announces First-Time Exhibition at the 14th Annual Dysautonomia International Conference in The Woodlands, Texas

Daxor Corporation announced its first-ever exhibition at the 14th Annual Dysautonomia International Conference, highlighting its FDA-cleared Blood Volume Analyzer (BVA) which provides objective plasma and red blood cell volume data to improve dysautonomia treatment precision. This appearance reinforces the shift towards data-driven autonomic disord…

SurancePlus Successfully Closes on Five (5) RWA Securities Offerings on Solana Raising $7.1 million and Expanding Tokenized RWA Platform

SurancePlus Successfully Closes on Five (5) RWA Securities Offerings on Solana Raising $7.1 million and Expanding Tokenized RWA Platform

Oxbridge Re Holdings Limited, through its subsidiary SurancePlus, successfully closed five private placements of tokenized reinsurance securities on the Solana blockchain, raising approximately $7.1 million. The offerings provide accredited U.S. and eligible non-U.S. investors exposure to reinsurance risk via blockchain-based tokenized real-world a…

Dave Appoints Gopi Kuchimanchi as Chief Technology Officer

Dave Appoints Gopi Kuchimanchi as Chief Technology Officer

Dave Inc., a Nasdaq-listed US neobank, announced the appointment of Gopi Kuchimanchi as its Chief Technology Officer. Gopi, previously VP of Technology, has been instrumental in advancing the company's AI underwriting engine and core technology infrastructure. His leadership is expected to strengthen Dave's technology platform and support multi-pro…

Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration

Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration

Allarity Therapeutics has achieved CLIA certification for its in-house laboratory in Denmark, a key step that allows the company to conduct its Drug Response Predictor (DRP®) testing internally. This certification is essential for biomarker testing in FDA registration clinical trials. Bringing DRP testing in-house is expected to reduce turnaround t…

Abacus Global Management to Tokenize Secondary Life Insurance Assets, Bringing On-Chain Infrastructure to Its Portfolio

Abacus Global Management to Tokenize Secondary Life Insurance Assets, Bringing On-Chain Infrastructure to Its Portfolio

Abacus Global Management (NYSE: ABX) has announced a plan to tokenize its secondary life insurance assets using blockchain technology. This initiative aims to create an immutable and transparent on-chain record for policy ownership and cash-flow rights, significantly improving transaction efficiency, transparency, and accessibility for institutiona…

Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor

Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor

Praxis Precision Medicines announces a strategic collaboration with Remagine Labs to develop an iontophoretic transdermal patch for their lead drug candidate ulixacaltamide, aimed at treating essential tremor (ET). This partnership seeks to enable a novel delivery system that may expand the patient population and lifecycle of the drug, complementin…

National Healthcare Properties Provides Transaction Updates

National Healthcare Properties Provides Transaction Updates

National Healthcare Properties, Inc. announced year-to-date acquisitions totaling approximately $197 million in senior housing operating portfolio (SHOP) communities, adding 882 assisted living units and 51 memory care units primarily in the Midwest, South, and Mid-Atlantic regions. Alongside these purchases, the company plans to sell a non-core SH…

Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI

Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI

Clearmind Medicine Inc. has announced successful formulation feasibility results for intranasal delivery of its lead therapeutic candidate MEAI, aimed at treating alcohol use disorder (AUD). The study demonstrates that MEAI can be stably formulated for intranasal administration, potentially enhancing therapeutic performance and patient convenience.…

Heidmar Maritime Holdings Corp. Expands Ship Management Platform

Heidmar Maritime Holdings Corp. Expands Ship Management Platform

Heidmar Maritime Holdings completed the acquisition of Q-Shipping B.V., a ship management and crewing business, adding nine vessels to its managed fleet and establishing an operational presence in the Netherlands, Turkey, and Ukraine. This acquisition supports Heidmar's asset-light growth strategy, expanding geographic reach and crewing capabilitie…

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Vivani Medical Enters into Agreement with Novo Nordisk to Evaluate NPM-139, a Miniature, Ultra Long-Acting Semaglutide Implant for Chronic Weight Management

Vivani Medical has entered into an agreement with Novo Nordisk to enable the evaluation of NPM-139, an ultra long-acting semaglutide implant developed using Vivani's NanoPortal technology targeting chronic weight management. The company plans to initiate a Phase 1 clinical trial comparing NPM-139 with Wegovy® injections to assess its safety, pharma…

ZenaTech’s ZenaDrone Advances Defense Drone Portfolio with Initial IQ Sphere Prototype for Autonomous GPS-Denied Inspections, Surveillance and Reconnaissance Missions

ZenaTech’s ZenaDrone Advances Defense Drone Portfolio with Initial IQ Sphere Prototype for Autonomous GPS-Denied Inspections, Surveillance and Reconnaissance Missions

ZenaTech, Inc. announced that its subsidiary ZenaDrone is developing the IQ Sphere, a compact autonomous drone designed for defense ISR missions and commercial inspections in GPS-denied and confined environments. The platform enhances situational awareness for defense operations and critical infrastructure inspection, expanding ZenaTech's autonomou…

Glass House Brands Completes First International Hemp Sale

Glass House Brands Completes First International Hemp Sale

Glass House Brands Inc., a leading U.S. cannabis company, completed its first international sale of smokeable CBD biomass to Europe, originating from its Camarillo Farm in California. The company emphasized compliance with California regulations and positioned its production for potential federal Medicare reimbursable CBD programs. This milestone r…

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)

MeiraGTx Holdings plc announced a strategic partnership with Oberland Capital Management for an investment of up to $400 million. The deal includes up to $375 million in non-dilutive capital and $25 million in equity to support the development and commercialization of key gene therapy programs targeting radiation-induced xerostomia (AAV2-hAQP1), X-…

Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026

Cytokinetics announced three late-breaking science presentations at the ESC Congress showcasing primary results from the pivotal Phase 3 ACACIA-HCM trial of aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy (HCM) patients. The company plans to engage regulatory authorities following positive topline results and will host an inves…

Cornerstone First Mortgage Switches to nCino's Mortgage Point of Sale to Support Its Next Phase of Growth

Cornerstone First Mortgage Switches to nCino's Mortgage Point of Sale to Support Its Next Phase of Growth

nCino, Inc. announced that Cornerstone First Mortgage has switched to using nCino's Mortgage Point of Sale platform to support its rapid growth and improve borrower experiences across its 49-state branch network. The platform's flexibility and AI-driven capabilities enable Cornerstone to streamline the loan process through digital verifications and…

Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery™ (EBD™) Technology and Early Alzheimer’s Disease Insights at the Alzheimer’s Association International Conference (AAIC®) 2026

Acumen Pharmaceuticals announced it will present three studies at the Alzheimer's Association International Conference 2026, showcasing progress in its Enhanced Brain Delivery (EBD) technology developed with JCR Pharmaceuticals and patient-centric research from its ALTITUDE-AD Phase 2 trial. These studies emphasize advancements in targeting toxic a…